Abstract: We anticipate the development of novel IGF-1-related therapy with minimal side effects. This review discusses recent findings on the role of IGF-1 in the cardiovascular (CVD) system, including both normal and pathological conditions. We also discuss progress in therapeutic interventions aimed at targeting the IGF axis and provide insights into the epigenetic regulation of IGF-1 mediated by microRNAs.
Introduction
Cardiovascular diseases (CVDs) remain the leading cause of global mortality. While Insulin-like Growth Factor 1 (IGF-1) has long been recognized for its influence on metabolism and cell survival, clinical data regarding its specific cardiovascular effects have historically been contradictory. This systematic review, published in Frontiers in Endocrinology, synthesizes decades of research to clarify the role of the "IGF-1 axis"—which includes the hormone itself, its receptors (IGF-1R), and its binding proteins (IGFBPs)—as a master regulator of cardiovascular homeostasis.
The GH/IGF-1 Axis and Cardiovascular Protection
The regulation of IGF-1 begins in the hypothalamus and pituitary gland, forming the Growth Hormone (GH)/IGF-1 axis. IGF-1 is primarily secreted by the liver in response to GH stimulation and exerts its effects through specific receptors and binding proteins.
As illustrated above, IGF-1 acts as a critical "survival factor" for the heart. It improves cardiac performance—including stroke volume and ejection fraction—and serves as a potent stabilizer of arterial plaques. By preventing the programmed cell death (apoptosis) of vascular smooth muscle cells (VSMCs), IGF-1 helps prevent the rupture of unstable plaques, a primary cause of myocardial infarction.
Evidence from Human Cohorts and Animal Models
The review draws upon extensive datasets to correlate IGF-1 levels with clinical outcomes:
- Human Studies: Data from the PRIME study (10,600 patients) and the Framingham Study indicate a "Goldilocks" relationship where low serum levels of free IGF-1 are strongly associated with increased risks of CVD and stroke. Quantitatively, every 45 ng/mL increase in serum IGF-1 correlates with a 9% reduction in overall cardiovascular risk.
- Animal Models: In Apoe-/- mice, IGF-1 infusion was found to reduce the extension of atherosclerotic lesions by approximately 30%, reinforcing its atheroprotective properties.
Epigenetic Regulation: The miRNA Rheostat
A novel contribution of this review is the emphasis on epigenetic regulation via microRNAs (miRNAs). These small molecules act as rheostats, fine-tuning the IGF-1 signaling axis. For instance, miR-1 controls IGF-1 expression in cardiac tissue, while miR-133a can stimulate IGF-1R expression. This suggests that targeting specific miRNAs may offer a more precise therapeutic pathway than systemic hormone administration.
Therapeutic Potential and Future Directions
Despite its protective benefits, systemic recombinant IGF-1 (rhIGF-1) therapy has faced challenges, including side effects like the aggravation of diabetic retinopathy. Furthermore, the lack of standardized assays for measuring "free" versus "total" IGF-1 complicates clinical application.
Future research is shifting toward nucleic acid-based therapeutic agents. By targeting the miRNAs that regulate the IGF-1 axis, researchers hope to confer localized protective effects on the heart and vasculature without the risks associated with systemic growth factor overstimulation. Maintaining optimal IGF-1 bioavailability remains a promising strategy for mitigating atherosclerosis and heart failure.
Summary updated